BRCA1 and carcinoma: The BRCA1/2 mutation prevalence is higher in young patients, patients with first-degree relatives with breast or ovarian carcinomas, patients with triple-negative carcinomas, patients with bilateral carcinomas, patients with concomitant breast and ovarian carcinomas, and high genetic risk patients [5, 8, 12, 15, 17, 19–21, 24].